Please contact us for more information or to learn if you are eligible to participate.
The purpose of the ARCADIA study is to test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial Cardiopathy.
Subjects will be followed for a minimum of 1.5 years and a maximum of 7 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.
Wady Aude, M.D.
Columbia University / National Institute of Neurological Disorders and Stroke (NINDS)
Type of Trial